Shonali Midha, MD, highlights data from the DREAMM-5 study during her presentation on the use of belantamab mafodotin for late relapse multiple myeloma.
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.